123 related articles for article (PubMed ID: 15809882)
1. Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases.
Auner HW; Zebisch A; Ofner P; Sill H; Linkesch W; Krause R
Ann Hematol; 2005 Aug; 84(8):532-7. PubMed ID: 15809882
[TBL] [Abstract][Full Text] [Related]
2. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
Gil L; Styczynski J; Komarnicki M
Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
[TBL] [Abstract][Full Text] [Related]
3. Infectious complications after autologous hematopoietic stem cell transplantation: comparison of patients with acute myeloid leukemia, malignant lymphoma, and multiple myeloma.
Auner HW; Sill H; Mulabecirovic A; Linkesch W; Krause R
Ann Hematol; 2002 Jul; 81(7):374-7. PubMed ID: 12185506
[TBL] [Abstract][Full Text] [Related]
4. Low incidence of secondary neoplasia after autotransplantation for lymphoproliferative disease: the role of pre-transplant therapy.
Laurenti L; Tarnani M; Chiusolo P; La Torre G; Garzia M; Zollino M; Zini G; Balducci M; Leone G; Sica S
Clin Transplant; 2008; 22(2):191-9. PubMed ID: 18339139
[TBL] [Abstract][Full Text] [Related]
5. The modification of high-dose therapy shortens the duration of neutropaenia by delay of leucocyte nadir.
Kiefer T; Krüger WH; Schüler F; Lotze C; Hirt C; Dölken G
Bone Marrow Transplant; 2006 Jun; 37(12):1087-91. PubMed ID: 16699528
[TBL] [Abstract][Full Text] [Related]
6. Fixed-dose single administration of Pegfilgrastim vs daily Filgrastim in patients with haematological malignancies undergoing autologous peripheral blood stem cell transplantation.
Staber PB; Holub R; Linkesch W; Schmidt H; Neumeister P
Bone Marrow Transplant; 2005 May; 35(9):889-93. PubMed ID: 15765110
[TBL] [Abstract][Full Text] [Related]
7. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma.
Vera-Llonch M; Oster G; Ford CM; Lu J; Sonis S
J Support Oncol; 2007 May; 5(5):231-5. PubMed ID: 17564153
[TBL] [Abstract][Full Text] [Related]
8. Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome.
González-Vicent M; Ramírez M; Sevilla J; Pérez A; Fernández S; Madero L; Díaz MA
Bone Marrow Transplant; 2004 Dec; 34(12):1051-5. PubMed ID: 15516943
[TBL] [Abstract][Full Text] [Related]
9. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation.
Kasbia G; Al-Gahtani F; Tay J; Labonté L; Tinmouth A; Ramsay T; Gillingham A; Yang L; Halpenny M; Giulivi A; McDiarmid S; Huebsch L; Allan DS
Transfusion; 2008 Nov; 48(11):2421-8. PubMed ID: 18673346
[TBL] [Abstract][Full Text] [Related]
10. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation.
Parody R; Martino R; Rovira M; Vazquez L; Vázquez MJ; de la Cámara R; Blazquez C; Fernández-Avilés F; Carreras E; Salavert M; Jarque I; Martín C; Martínez F; López J; Torres A; Sierra J; Sanz GF;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):734-48. PubMed ID: 16785063
[TBL] [Abstract][Full Text] [Related]
11. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes.
Majhail NS; Parks K; Defor TE; Weisdorf DJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1038-46. PubMed ID: 17067910
[TBL] [Abstract][Full Text] [Related]
12. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
14. Factors influencing engraftment in autologous peripheral hematopoetic stem cell transplantation (PBSCT).
Ergene U; Cağirgan S; Pehlivan M; Yilmaz M; Tombuloğlu M
Transfus Apher Sci; 2007 Feb; 36(1):23-9. PubMed ID: 17292672
[TBL] [Abstract][Full Text] [Related]
15. Low infectious morbidity in patients with heavily pretreated hematological malignancies receiving autologous peripheral blood stem cell transplantation without antimicrobial prophylaxis.
Yeh SP; Chiu CF; Lo WJ; Lin CL; Hsueh CT; Liao YM; Shen YC
Ann Hematol; 2003 Jan; 82(1):24-9. PubMed ID: 12574960
[TBL] [Abstract][Full Text] [Related]
16. Increased risk for invasive aspergillosis in patients with lymphoproliferative diseases after autologous hematopoietic SCT.
Gil L; Kozlowska-Skrzypczak M; Mol A; Poplawski D; Styczynski J; Komarnicki M
Bone Marrow Transplant; 2009 Jan; 43(2):121-6. PubMed ID: 18794866
[TBL] [Abstract][Full Text] [Related]
17. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
18. Fulminant Epstein-Barr virus (EBV)-associated T-cell lymphoproliferative disorder with hemophagocytosis following autologous peripheral blood stem cell transplantation for relapsed angioimmunoblastic T-cell lymphoma.
Awaya N; Adachi A; Mori T; Kamata H; Nakahara J; Yokoyama K; Yamada T; Kizaki M; Sakamoto M; Ikeda Y; Okamoto S
Leuk Res; 2006 Aug; 30(8):1059-62. PubMed ID: 16330097
[TBL] [Abstract][Full Text] [Related]
19. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
20. [A prospective and randomized study of two conditioning regimens in treatment of severe systemic autoimmune diseases with autologous peripheral blood stem cell transplantation].
Zhang W; Zhou DB; Zhao Y; Leng XM; Zhang JP; Jiang Y; Jiao L; Wang SJ; Duan MH; Tang FL; Shen T
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1689-92. PubMed ID: 17825150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
